Exelixis (EXEL) Q4 2025: Cabo Franchise Grows 17% as Zanza Pipeline Accelerates
Exelixis delivered a pivotal quarter, with the Cabo franchise driving double-digit growth while the company advanced Zanzalitinib toward regulatory and commercial inflection points. Management’s franchise-building strategy is yielding operational leverage, but execution risk remains as the pipeline broadens and reimbursement complexity rises. The year ahead hinges on regulatory outcomes, franchise expansion, and Exelixis’s ability to translate pipeline momentum into durable market share.
Summary
- Franchise Model Deepens: Multi-tumor strategy advances, with Zanza poised to become a second flagship oncology brand.
- Pipeline and Commercial Buildout: Accelerated investments in GI sales and pivotal trials underpin growth but raise near-term cost intensity.
- Regulatory and Market Access Risks: Execution on NDA filings and reimbursement changes will determine the pace and scale of future expansion.
Business Overview
Exelixis is a biotechnology company focused on developing and commercializing therapies for solid tumor oncology. Its core revenue comes from Cabozantinib, a tyrosine kinase inhibitor (TKI) marketed as Cabometyx, which is the leading TKI in renal cell carcinoma (RCC) and a market leader in neuroendocrine tumors (NETs). The company is expanding its portfolio with Zanzalitinib (Zanza), a next-generation TKI, and is actively building out multiple oncology franchises across genitourinary (GU) and gastrointestinal (GI) tumor types.
Performance Analysis
Exelixis posted robust revenue growth in Q4 and FY2025, anchored by the continued outperformance of the Cabo franchise. U.S. Cabo net product revenue grew at a double-digit pace, with notable strength in both RCC and the newly launched neuroendocrine tumor indication. International royalties and partner revenues contributed additional upside, reflecting the global reach of the brand.
Operating expenses rose sequentially, primarily driven by higher manufacturing, NDA filing fees, personnel, and marketing costs—reflecting both pipeline advancement and commercial expansion. Gross-to-net deductions improved in the quarter due to lower 340B and PHS volume, but management guided to higher gross-to-net rates in 2026 due to Medicare Part D designations and anticipated channel mix shifts.
- Cabo Franchise Dominance: Maintained #1 TKI position in RCC and NETs, with TRx share rising to 46% and volume growth outpacing the broader TKI market.
- Neuroendocrine Tumor Uptake: Exceeded $100 million in annual NET revenue in its first year, with opportunity for further penetration in community settings as the GI sales team expands.
- Share Repurchases: Nearly $1 billion in stock was repurchased, underscoring management’s conviction in undervaluation and capital return discipline.
Exelixis exits 2025 with a strong balance sheet, ample liquidity for pipeline investment, and a remaining $590 million in buyback authorization. However, rising operating costs and evolving reimbursement dynamics will require careful navigation as the company scales new franchises.
Executive Commentary
"ExoLexus has a singular focus to build a multi-franchise business in solid tumor oncology based on the foundation of cabozantinib, the potential of zanzolintinib, and the depth of our early stage pipeline."
Mike Morrissey, President and Chief Executive Officer
"Gross to net for the Cabozante franchise in the fourth quarter of 2025 was 28.5%, which is lower than the gross to net we experienced in the third quarter of 2025. We estimate that our gross to net for the full year of 2026 will be between 31% and 32%."
Chris Senner, Chief Financial Officer
Strategic Positioning
1. Franchise Expansion Across Tumor Types
Exelixis is doubling down on a franchise model, aiming to entrench leadership in GU oncology while aggressively moving into GI cancers. The company’s strategy is to build depth (multiple indications per product) and breadth (multiple modalities and tumor types), using Cabo’s dominance as a template for Zanza’s potential in CRC and beyond.
2. Zanzalitinib Pipeline Acceleration
Zanza is positioned as the next growth engine, with seven pivotal trials ongoing or planned, including combinations with immunotherapy (IO) agents. The NDA for Zanza plus atezolizumab in third-line colorectal cancer has been accepted, with a PDUFA date set for December. Exelixis is also initiating studies in earlier-stage CRC (Stellar 316) and rare tumors, aiming to create a multi-indication franchise.
3. Commercial Infrastructure and Community Penetration
Investment in sales force expansion, especially in GI oncology, is intended to drive further share gains in NETs and prepare for Zanza’s launch in CRC. Management sees significant upside in community settings, where market share remains underpenetrated compared to academic centers.
4. Capital Allocation and Business Development
Exelixis is pursuing back-end-loaded, pay-for-success deals to access late-stage GU and GI assets, while maintaining flexibility for opportunistic buybacks. The company’s balance sheet is positioned to support both internal pipeline advancement and external innovation, though the pace of business development will be dictated by strategic fit and valuation discipline.
5. Regulatory and Reimbursement Navigation
Gross-to-net headwinds are set to intensify in 2026, as Medicare Part D redesign and 340B channel variability impact realized revenue per script. The company’s designation as a small manufacturer provides a temporary buffer, but multi-product launches may erode this advantage over time.
Key Considerations
Exelixis’s quarter was defined by franchise momentum, pipeline acceleration, and a proactive approach to commercial and regulatory complexity. The company is executing on its vision of building multiple oncology franchises, but the transition from a single-product to a multi-product model introduces new execution risks and demands.
Key Considerations:
- Pipeline Readouts Will Drive Valuation: Multiple pivotal Zanza trials (Stellar 303, 304, 316) and regulatory milestones will be the primary catalysts over the next 12 months.
- Community Market Penetration Is Critical: Growth in NETs and CRC will depend on deeper reach into community oncology, not just academic centers.
- Gross-to-Net and Reimbursement Complexity Rising: Medicare Part D redesign and 340B variability will impact realized revenue, requiring ongoing optimization of channel strategy.
- Capital Return Remains a Priority: Share repurchases signal confidence but must be balanced with investment in pipeline and business development opportunities.
Risks
Regulatory outcomes for Zanza, especially in CRC and RCC, represent binary risk and could reshape the growth narrative. Reimbursement headwinds, including higher gross-to-net deductions and evolving Medicare/340B policies, may pressure margins. Pipeline execution risk rises as the company juggles multiple pivotal trials and commercial launches, while competitive intensity in RCC and CRC remains high with new entrants and combination regimens.
Forward Outlook
For Q1 2026, Exelixis guided to:
- Gross-to-net deductions rising to 31-32% for the full year, reflecting Medicare Part D and 340B channel dynamics.
- Continued operating expense growth to support pipeline advancement and commercial expansion.
For full-year 2026, management maintained guidance:
- Robust top-line growth driven by Cabo in RCC and NETs, with upside potential from Zanza regulatory milestones.
Management highlighted several factors that will shape results:
- Key regulatory events for Zanza, including the December PDUFA date and pivotal trial readouts.
- Ongoing expansion of the GI sales team and focus on community oncology market share gains.
Takeaways
Exelixis is at a critical inflection point, leveraging its Cabo franchise to fund and scale a multi-pronged pipeline while navigating reimbursement and operational complexity.
- Execution on Pipeline and Commercial Expansion: The ability to translate Zanza’s clinical promise into commercial success will determine whether Exelixis can replicate Cabo’s dominance in new tumor types.
- Reimbursement and Channel Dynamics: Higher gross-to-net rates and Medicare changes will pressure near-term margins, requiring agile channel management and pricing discipline.
- Future Watchpoint: Investors should monitor pivotal trial outcomes, the pace of community market share gains, and the impact of regulatory and reimbursement shifts on realized revenue and operating leverage.
Conclusion
Exelixis exits 2025 with strong franchise momentum, a deepening pipeline, and a sharpened commercial focus. The transition to a multi-product, multi-franchise oncology business is underway, but the next twelve months will test the company’s ability to execute on regulatory, commercial, and operational fronts.
Industry Read-Through
Exelixis’s franchise-building playbook reflects a broader industry trend of oncology companies seeking to maximize asset value through indication expansion, combination regimens, and deeper market segmentation. Gross-to-net and reimbursement headwinds are not unique to Exelixis; all oncology players with Medicare and 340B exposure will face similar margin pressures as policy shifts accelerate. Community market penetration is increasingly critical for growth, especially as academic center share saturates. Finally, the emphasis on pay-for-success business development and capital return underscores a sector-wide focus on disciplined capital allocation in the face of rising R&D and commercial costs.